Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;23(2):745-749.
doi: 10.1016/j.jtha.2024.10.033. Epub 2024 Nov 20.

Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document

Miguel Escobar  1 , Riitta Lassila  2 , Carine Bekdache  3 , Tarek Owaidah  4 , Michelle Sholzberg  5
Affiliations
Free article
Review

Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document

Miguel Escobar et al. J Thromb Haemost. 2025 Feb.
Free article

Abstract

Here, we summarize the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document recommendations on antithrombotic therapy for cardiovascular indications among patients with hemophilia. This summary includes a discussion on primary and secondary prevention of venous and arterial thrombosis. The guidance document considers distinct and controversial challenges presented by various clinical scenarios in this aging patient population and provides thoughtful recommendations to assist the hemophilia care provider in clinical decision-making.

Keywords: antithrombotic therapy; cardiovascular disease; clinical guidelines; hemophilia; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interests M.E.: consultancy fees from Novo Nordisk, BioMarin, CSL Behring, Genentech/Roche, Sanofi, Takeda, Pfizer, Bayer, Hemobiologics/LFB, Kedrion, and UniQure. Participated in clinical trials sponsored by Novo Nordisk, UniQure, Takeda, Bayer, Genentech/Roche, CSL Behring, and Sanofi. R.L.: consultancy fees from Alexion, AstraZeneca, Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Roche, Sanofi, SOBI, and Takeda. T.O.: consulting fees from Bayer, Sobi, and Novo Nordisk. M.S.: unrestricted research funding from Octapharma, Pfizer, and Amgen (to the institution); honoraria from advisory boards from Amgen, Novartis, Octapharma, Pfizer, and Amgen. C.B.: none. M.S.: unrestricted research funding from Octapharma, Pfizer, and Amgen (to the institution); honoraria from advisory boards from Amgen, Novartis, Octapharma, Pfizer, and Amgen.

Substances

LinkOut - more resources